10/14/2025

Janusmed fosterpåverkan

Janusmed fosterpåverkan – Reboxetin

Janusmed fosterpåverkan tillhandahåller bedömningar av eventuella risker för fostret, när en gravid kvinna använder olika läkemedel. Observera att texterna är generella, och att en bedömning måste göras i varje enskilt fall. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed fosterpåverkan och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Reboxetin

Reboxetin

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Berlin M, Kronenfeld N, Dinavitser N, Brik A, Cohen R, Fanny O et al. #15 The safety of reboxetine during pregnancy and lactation – case series. Reprod Toxicol. 2019;88:138.

  2. Lennestål R, Källén B. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol. 2007;27:607-13..

  3. Grigoriadis S, VonderPorten EH, Mamisashvili L, Roerecke M, Rehm J, Dennis CL et al. Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence. J Clin Psychiatry. 2013;74:e293-308.

  4. Myles N, Newall H, Ward H, Large M. Systematic meta-analysis of individual selective serotonin reuptake inhibitor medications and congenital malformations. Aust N Z J Psychiatry. 2013;47(11):1002-12.

  5. Kolding L, Ehrenstein V, Pedersen L, Sandager P, Petersen OB, Uldbjerg N,Pedersen LH. Antidepressant use in pregnancy and severe cardiac malformations: Danish register-based study. BJOG. 2021 Nov;128(12):1949-1957.

  6. Rommel AS, Momen NC, Molenaar NM, Agerbo E, Bergink V, Munk-Olsen T et al. Antidepressant use during pregnancy and risk of adverse neonatal outcomes: A comprehensive investigation of previously identified associations. Acta Psychiatr Scand. 2022;145(6):544-556.

  7. Kautzky A, Slamanig R, Unger A, Höflich A. Neonatal outcome and adaption after in utero exposure to antidepressants: A systematic review and meta-analysis. Acta Psychiatr Scand. 2022;145(1):6-28.

  1. Berlin M, Kronenfeld N, Dinavitser N, Brik A, Cohen R, Fanny O et al. #15 The safety of reboxetine during pregnancy and lactation – case series. Reprod Toxicol. 2019;88:138.
  2. Lennestål R, Källén B. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol. 2007;27:607-13..
  3. Grigoriadis S, VonderPorten EH, Mamisashvili L, Roerecke M, Rehm J, Dennis CL et al. Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence. J Clin Psychiatry. 2013;74:e293-308.
  4. Myles N, Newall H, Ward H, Large M. Systematic meta-analysis of individual selective serotonin reuptake inhibitor medications and congenital malformations. Aust N Z J Psychiatry. 2013;47(11):1002-12.
  5. Kolding L, Ehrenstein V, Pedersen L, Sandager P, Petersen OB, Uldbjerg N,Pedersen LH. Antidepressant use in pregnancy and severe cardiac malformations: Danish register-based study. BJOG. 2021 Nov;128(12):1949-1957.
  6. Rommel AS, Momen NC, Molenaar NM, Agerbo E, Bergink V, Munk-Olsen T et al. Antidepressant use during pregnancy and risk of adverse neonatal outcomes: A comprehensive investigation of previously identified associations. Acta Psychiatr Scand. 2022;145(6):544-556.
  7. Kautzky A, Slamanig R, Unger A, Höflich A. Neonatal outcome and adaption after in utero exposure to antidepressants: A systematic review and meta-analysis. Acta Psychiatr Scand. 2022;145(1):6-28.